Michael Bossert (Enamine Ltd. (UA))

Bossert, Michael (Enamine Ltd 201201 Business Development Director)

	Organisation	Enamine Ltd. (UA)
	Product	chemical compound library (availability)
	Product 2	chemical compound library (production)

Enamine Ltd.. (1/31/12). "Press Release: Enamine Provides Large Novel Diverse Compound Screening Library to Extend Relationship with BioFocus". Kiev.

Enamine Ltd, a leading provider of screening compounds and chemical building blocks, today announced it has extended its long-standing relationship with BioFocus, with the acquisition by BioFocus of a large new compound screening library. The library will be available to BioFocus HTS collaborators in early 2012.

Kate Hilyard, Vice President Biological Sciences, BioFocus, commented: "We have been impressed by the quality of Enamine's compound collection during our multiyear collaboration. Their strong support services and ability to provide novel compounds using novel chemistry have also been factors driving our decision to extend the current agreement."

Michael Bossert, Business Development Director, Enamine, said: "We are very pleased that BioFocus has decided to continue working with us, which we see as a testament to our growing reputation among professional screening companies and academic research centers. We look forward to a successful renewed relationship."

About Enamine

Established in Kiev in 1991, Enamine is a chemical company supplying novel screening compounds to the pharmaceutical, cosmetic, nutritional and agrochemical industries. Enamine's design and synthesis capabilities allow the Company to add more than 250,000 new organic compounds to its catalogue each year, with 2 million compounds currently available. The Company offers collaborative expertise to exclusively design and supply libraries of new, potentially bioactive organic compounds and building blocks, in addition to furnishing in-house chemical libraries to screening centers worldwide.

About BioFocus

BioFocus provides integrated drug discovery that delivers pre-clinical drug candidates in all therapeutic areas with strong capability in neurodegenerative diseases, inflammatory diseases and with a growing track record of delivering candidates against rare and neglected diseases.

BioFocus has advanced and comprehensive drug discovery capabilities that are applied to client projects to deliver targets, hits, leads and candidate pre-clinical drugs. The company employs over 220 exceptionally qualified and industry experienced scientists at its three research centers in the UK, Switzerland and the Netherlands.

Since its foundation in 1997, BioFocus has striven to produce high quality data for its clients and this quality is assured by ISO9001 qualification validated by regular, independent inspection of all BioFocus research centers.

Contacts
Michael Bossert
Director Business Development,
Enamine Ltd
Email: m.bossert@enamine.net

On behalf of BioFocus
Katie Odgaard
Zyme Communications
Tel: +44 7787 502 947
Email: katie.odgaard@zymecommunications.com